Syndax anticipates Revuforj could exceed $2B in U.S. peak annual net revenue as post-transplant maintenance builds

Earnings Call Insights: Syndax Pharmaceuticals (SNDX) Q3 2026

Management View

• “Syndax delivered another strong quarter of commercial growth and pipeline momentum. Total revenue reached $83 million this quarter, up 82% year-over-year… we are moving decisively towards profitability.” (CEO & Director Michael Metzger)
• “Revuforj net revenue grew to $61 million in the third quarter… we expect Revuforj to account for the vast majority, more than 80%, of the revenue for the class this quarter.” (CEO Metzger)
• “We achieved our seventh consecutive quarter of double-digit quarter-over-quarter Revuforj net revenue growth, driven by a 20% increase in new patients and an increasing number of patients resuming Revuforj after stem cell transplant.” (CEO Metzger)
• “Niktimvo net revenue grew to $67 million in the third quarter… Our 50% share of Niktimvo net profit delivered $23 million in collaboration revenue.” (CEO Metzger)
• “Keith Goldan has decided to retire as Chief Financial Officer… I am pleased to welcome Aaron Ondrey as our new CFO effective Monday, November 9.” (CEO Metzger)
• “Total revenue for the third quarter of 2026 was $83.3 million… Revuforj net revenue grew to $60.7 million, and Niktimvo collaboration revenue to $22.6 million.” (CFO, Treasurer & Principal Accounting Officer Keith Goldan)

Outlook

• “With anticipated front-line indications, we expect Revuforj could exceed $2 billion in peak annual net revenue in the U.S. alone.” (CEO Metzger)
• “We expect to publish Revuforj data in relapsed/refractory NUP98-rearranged acute leukemia in the fourth quarter.” (CEO Metzger)
• “We now expect the top line results from the Phase II trial of axatilimab in combination with ruxolitinib to be reported at a medical meeting in the first quarter of 2027.” (Head of R&D and Chief Medical Officer Nicholas Botwood)
• “We expect both molecules are on track to enter the clinic next year… on track to submit the IND for 4321 by the end of 2026 and the IND for 62122 next year.” (Dr. Botwood)

Financial Results

• “Total revenue for the third quarter of 2026 was $83.3 million… Revuforj net revenue grew to $60.7 million, and Niktimvo collaboration revenue to $22.6 million.” (CFO Goldan)
• “The Niktimvo margin contribution… was approximately 34% this quarter… going forward, we do expect the margin contribution to be in the low-to-mid-30% range, an increase from the 25% to 30% range we guided to earlier in the launch.” (CFO Goldan)
• “Our guidance for total R&D plus SG&A expenses for 2026 remains approximately $400 million, excluding the impact of $50 million in estimated noncash stock compensation expense.” (CFO Goldan)
• “We ended the third quarter in a strong cash position with $551 million in cash, equivalents and investments.” (CFO Goldan)

Q&A

• [Dilp Dales], JPMorgan: “what are you seeing” on post-transplant resumption and “expectations” for BEAT AML/SAVE? CEO Metzger: “50%… 60%… now getting maintenance… where we expect it to go, 70% to 80% at maturity”; Dr. Botwood: watch “tolerability,” “the CR rate,” and “the survival data.”
• Faisal Khurshid, Jefferies: competition vs. J&J/Sumitomo at ASH and timing clarity for front-line. CEO Metzger: “we have not seen data… we'll reserve judgment… our view on competition is that it's unlikely to be differentiated”; later added timing detail “will come in time… it doesn't seem to be the right time to necessarily update.”
• Ellen Horste, TD Cowen: NPM1 duration and post-transplant benefit. CEO Metzger: “we would expect to be in the 6 to 12 month range”; added non-transplant responders are “7-plus months of duration.”
• Stephen Willey, Stifel: durability of “40%” NPM1 transplant rate; and axatilimab+rux front-line cGVHD benchmarks. CEO Metzger: “we are treating patients earlier… treating them in combination… getting them to a response”; Dr. Botwood: steroids benchmark “around 40%” response at 6 months and steroid EFS “probably… 6 to 7 months,” with “3 to 4 months” increment “quite clinically meaningful.”
• Gustave Diep, Barclays: AGAVE-201 reduced-frequency axatilimab dosing significance; and whether combos link to deeper outcomes commercially. Dr. Botwood: “transition… to a monthly IV… could ultimately inform guidelines and potentially even inform labeling”; on combos: “you get much higher response rates… give the patients the opportunity to go to transplant.”
• Joohwan Kim, Citi: where the “20%” new-patient growth came from and enrollment pacing EVOLVE-2 vs. REVEAL. CCO Closter: “It's coming from all over”; CEO Metzger: “We haven't updated our guidance… but both are moving along well.”
• Salim Syed, Mizuho: CFO retirement rationale. CFO Goldan: “this was purely a personal decision… not a retirement in the loose setting.”
• Andres Maldonado, H.C. Wainwright: transplant-rate gap NPM1 vs. KMT2A and combination regimen mix. CEO Metzger: NPM1 transplant “could… get to 40%, 50%” and resumption “maybe 60%, 70%”; Dr. Botwood: combos are “most commonly… Ven/Aza.”
• [Jackie], Bank of America: timing of headwind-to-tailwind from transplant pauses. CEO Metzger: “2027 is where you'll see the greatest impact.”
• Mayank Mamtani, B. Riley: 4Q TRx vs NRx and front-line endpoints/maintenance crossover. CEO Metzger: “We are not going to comment on the fourth quarter”; Dr. Botwood: EVOLVE-2 endpoints are “CR… overall survival,” REVEAL includes “MRD-negative CR” and “event-free survival,” and “The studies do not allow for formal crossover.”

Sentiment Analysis

• Analysts slightly negative: questions pressed on competition, durability of elevated transplant rates, timing of front-line data, and near-term trends; examples include “how do you think about those programs” (Jefferies Khurshid) and “do you think that this is a durable trend?” (Stifel Willey).
• Management slightly positive: management repeatedly emphasized confidence and leadership, including “we are confident Revuforj will remain the menin inhibitor of choice” (CEO Metzger) and “we are feeling extremely confident” (Dr. Botwood).
• Versus prior quarter, management was more explicit on operational change (CFO transition) and reiterated reluctance to provide timelines, stating “it doesn't seem to be the right time to necessarily update on that” (CEO Metzger).

Quarter-over-Quarter Comparison

• Current call highlighted acceleration in Revuforj new patients (“about 300 new patients… up approximately 20% quarter-over-quarter”) (CCO Steven Closter) versus the prior call describing Q2 “fluctuation in the number of new patients initiating therapy” (CEO Metzger).
• Current call introduced a clearer NPM1 transplant dynamic (“about 40% of our NPM1 patients are proceeding to transplant”) (CCO Closter) while the prior call focused more on KMT2A post-transplant stacking and did not provide an NPM1 transplant-rate figure.
• Margin expectations moved: Q3 described margin contribution “approximately 34%… low-to-mid-30% range” (CFO Goldan) versus Q2 guidance of “25% to 30% range” (CFO Goldan).

Risks and Concerns

• “As patients pause treatment to receive a transplant, this creates a short-term headwind” (CEO Metzger), with management framing the mitigation as resumption and longer duration post-transplant.
• On competitive read-throughs, CEO Metzger said, “we have not seen data obviously yet, so we'll reserve judgment until we do.”
• On timeline visibility, CEO Metzger said updates will come later and “it doesn't seem to be the right time to necessarily update.”
• CFO Goldan noted the Q3 margin was “slightly benefited by the impact of a one-time, nonrecurring adjustment,” implying quarter-specific variability.

Final Takeaway

Syndax management emphasized Q3 revenue growth driven by Revuforj and Niktimvo, reiterated expectations that post-transplant maintenance can extend duration and become a bigger growth driver into 2027, and pointed to multiple near-term catalysts (ASH data, a 4Q NUP98 publication, and a Phase II axatilimab+rux update in Q1 2027). Management also announced a CFO transition effective November 9 and updated the expected Niktimvo margin contribution range to the low-to-mid-30%s following a quarter that included a one-time benefit.

Read the full Earnings Call Transcript

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.